New hope for kidney cancer: ivonescimab trial launches

NCT ID NCT06940518

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 13, 2026 · Updated 3 times

Summary

This Phase 2 trial tests the drug ivonescimab in 40 people with advanced clear cell renal cell carcinoma that has worsened after prior treatment. The goal is to see if the drug can help control the cancer and to monitor any side effects. Participants receive ivonescimab by IV infusion.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ivonescimab
What this could lead to: If it works, this could offer a new treatment option for advanced kidney cancer that has not responded to prior therapies.
What could go wrong: This is an early Phase 2 trial with only 40 participants, so results may not apply to everyone. The drug may cause side effects or fail to control the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

clear cell renal carcinoma nonpapillary renal cell carcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLEAR CELL RENAL CARCINOMA IVONESCIMAB

Contacts and locations

Locations

MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.